<DOC>
	<DOCNO>NCT02343549</DOCNO>
	<brief_summary>All patient complete best standard care radiation , temozolomide bevacizumab ( 6 week ) . Within two week completion initial treatment period , study patient fit NovoTTF-100A System treat continuously . They treat TTFields 12 month average 18 hour per day . The patient may elect take treatment break total 3 day per month , month still compliance . This consist wear four electrically insulated electrode array head . The patient also continue maintenance temozolomide/ bevacizumab .</brief_summary>
	<brief_title>A Phase II Study Optune ( NovoTTF ) Combination With Bevacizumab ( BEV ) Temozolomide ( TMZ ) Patients With Newly Diagnosed Unresectable Glioblastoma ( GBM )</brief_title>
	<detailed_description>This study carry two stage . The first stage enroll cohort 22 patient . The FDA review safety data first 15 patient enrollment first cohort . Enrollment interim analysis first cohort patient complete within 15 month study commencement . Upon FDA approval favorable interim analysis follow subsequent protocol/consent amendment ( applicable ) , second stage enroll cohort 24 patient complete within 15 month stage 2 commencement . The overall duration study expect longer 30 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>At least 22 year age Have undergo brain biopsy via stereotactic open technique Pathological evidence GBM use WHO classification criterion Planned 6 week concurrent chemoradiotherapy postbiopsy concomitant temozolomide ( 4570Gy ) Karnofsky scale great equal 70 Life expectancy least 3 month Baseline hemoglobin &gt; 8.0 gm/dL ( without transfusion ) Adequate coagulation define PT INR &lt; 1.5 time upper limit normal Signed inform consent Able start bevacizumab least 2 week 4 week date biopsy Able tolerate MRI brain measurable disease . Participants childbearing age must use effective contraception least 6 month follow completion treatment . Exclusion Criteria Enrolled another clinical treatment trial Pregnant Breastfeeding Any malignancy aside localize basal cell squamous cell carcinoma skin Significant comorbidities baseline would prevent maintenance temozolomide Thrombocytopenia ( platelet count &lt; 100 x 103 ) Neutropenia ( absolute neutrophil count &lt; 1.5 x 103 ) CTC grade 4 nonhematological toxicity ( except alopecia , nausea , vomit ) Significant liver function impairment AST ALT &gt; 3 time upper limit normal Total bilirubin &gt; 2 time upper limit normal Significant renal impairment ( serum creatinine &gt; 1.7 mg/dL ) Implanted pacemaker , programmable shunt , defibrillator , deep brain stimulator , implant electronic device brain , document clinically significant arrhythmia . Infratentorial tumor Evidence increase intracranial pressure ( midline shift &gt; 5mm , clinically significant papilledema , vomit nausea , reduce level consciousness ) History hypersensitivity reaction temozolomide history hypersensitivity DTIC hydrogel Inability adequately cover treatment area TTFields ( Tumor Treating Fields ) Inability wear NovoTTF100A System average 18 hour per 24 hour Currently take cytotoxic medication , nonsteroidal antinflammatory drug ( NSAIDS ) , enzyme inducing anticonvulsant . Currently take anticoagulant bloodthinners ( Coumadin ) Subjects meet follow bevacizumabspecific contraindication ineligible study entry : Inadequately control hypertension ( define systolic blood pressure great equal 150 and/or diastolic blood pressure &gt; 100 mmHg ) Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior study enrollment History hemoptysis ( great equal half teaspoon bright red blood per episode ) within 1 month prior study enrollment Evidence bleed diathesis coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure significant traumatic injury within 28 day prior 1st bevacizumab infusion anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation within 6 month prior study enrollment Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria screening demonstrate either urine protein : creatinine ( UPC ) ratio great equal 1.0 screening OR urine dipstick proteinuria great equal 2 ( patient discover great equal 2 great proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate less equal 1g protein 24 hour eligible ) . Known hypersensitivity component bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>